<DOC>
	<DOCNO>NCT00754650</DOCNO>
	<brief_summary>This single arm study evaluate bone marrow response , safety , tolerability 6 month treatment Avastin ( bevacizumab ) monotherapy patient chronic lymphocytic leukemia . Patients receive 8 cycle ( 21 day duration ) Avastin monotherapy ( 15mg/kg ) 6 month follow-up .</brief_summary>
	<brief_title>A Proof Concept Study Safety , Tolerability , Efficacy Avastin ( Bevacizumab ) Patients With Chemo-naive Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Male female patient , ≥ 18 year age . Bchronic lymphocytic leukemia yet require treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . No previous treatment chronic lymphocytic leukemia ( CLL ) chemotherapy , radiotherapy , immunotherapy . Life expectancy &gt; 6 month . Central nervous system ( CNS ) involvement lymphoma evidence spinal cord compression . Computed tomography ( CT ) scan base evidence tumor invade major blood vessel . Gastrointestinal ( GI ) tract involvement CLL . Active viral , bacterial , fungal infection . Uncontrolled hypertension , cerebrovascular accident/stroke ( ≤ 6 month prior randomization ) , myocardial infarction ( ≤ 6 month prior randomization ) , unstable angina ( ≥ New York Heart Association ( NYHA ) Grade IV ) , thrombosis within 6 month enrollment , NYHA Grade II congestive heart failure , serious cardiac arrhythmia require ongoing medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>